2-Oct-2026
Arbutus gains on plans to buy back 46M shares in tender offer
Seeking Alpha News (Wed, 30-Sep 12:51 PM ET)
Globe Newswire (Wed, 23-Sep 7:00 AM ET)
Globe Newswire (Wed, 23-Sep 7:00 AM ET)
Globe Newswire (Tue, 8-Sep 6:00 AM ET)
Globe Newswire (Tue, 8-Sep 6:00 AM ET)
Globe Newswire (Sun, 6-Sep 1:00 AM ET)
Globe Newswire (Sun, 6-Sep 1:00 AM ET)
Globe Newswire (Thu, 27-Aug 3:29 PM ET)
Globe Newswire (Thu, 27-Aug 3:28 PM ET)
Globe Newswire (Wed, 26-Aug 11:11 AM ET)
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Roivant Sciences Ltd. - Common Shares trades on the NASDAQ stock market under the symbol ROIV.
As of October 2, 2026, ROIV stock price climbed to $35.72 with 4,153,817 million shares trading.
ROIV has a beta of 0.56, meaning it tends to be less sensitive to market movements. ROIV has a correlation of 0.03 to the broad based SPY ETF.
ROIV has a market cap of $25.80 billion. This is considered a Large Cap stock.
Last quarter Roivant Sciences Ltd. - Common Shares reported $1 million in Revenue and -$.34 earnings per share. This fell short of revenue expectation by $-903,840 and exceeded earnings estimates by $.03.
In the last 3 years, ROIV traded as high as $42.50 and as low as $8.25.
The top ETF exchange traded funds that ROIV belongs to (by Net Assets): IJH, VTI, VB, XMMO, VBK.
ROIV has outperformed the market in the last year with a return of +123.5%, while the SPY ETF gained +16.1%. However, in the most recent history, ROIV shares have underperformed the stock market with its stock returning +1.7% in the last 3 month period and -10.2% for the last 2 week period, while SPY has returned +3.6% and +1.0%, respectively.
ROIV support price is $34.63 and resistance is $36.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ROIV shares will trade within this expected range on the day.